Trial Profile
Assessing The Effect of Apixaban on Endogenous Fibrinolysis in Patients With Non-Valvular Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Aspirin; Warfarin
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- 06 Feb 2019 Status changed from recruiting to completed.
- 25 Oct 2017 Status changed from not yet recruiting to recruiting.
- 29 Jun 2017 New trial record